Background: Heart failure (HF) following an acute myocardial infarction (post-MI HF) has
been studied as an additional sub-type of HF to broaden the indications for HF drugs. Post …

Background Following the availability of new drugs for chronic heart failure (HF) with
reduced ejection fraction (HFrEF), we sought to provide an updated and comparative …

Objective: Heart failure (HF) is a main contributor of cardiovascular morbidity and mortality
among patients with type 2 diabetes mellitus (T2DM), while T2DM among patients with HF …

The European Society of Cardiology (ESC) Congress 2021, although still online due to the
Covid-19 pandemic, was an extraordinary theatre for the presentation of practice-changing …

The pace of research has accelerated for chronic diseases like heart failure (HF), kidney
disease, and diabetes. Multiple trials showing benefits provide a robust evidence base for …

Objectives Evidence for the efficacy of pharmacological therapies for heart failure with
reduced ejection fraction (HFrEF) is growing. However, there is no consensus on the most …

Lesny P, Luknar M, Gonçalvesova E. Is left ventricular ejection fraction still a limiting factor in
the treatment of heart failure? Cardiology Lett. 2023; 32 (3): 185–191 Abstract. Left …

Summary Background Both DAPA-HF (assessing dapagliflozin) and EMPEROR-Reduced
(assessing empagliflozin) trials showed that sodium-glucose co-transporter-2 (SGLT2) …

Sažetak In the year 2021, the universal definition and classification of heart failure (HF) was
published that defines HF as a clinical syndrome with symptoms and/or signs caused by a …

Objective: Results from large placebo-controlled randomized trials in patients with heart
failure with mid-range ejection fraction (HFmrEF) and HF with preserved EF (HFpEF) have …